Diagnosis of polymyalgia rheumatica and giant cell arteritis using FDG PET and PET / CT imaging – Twelve-year experience of one diagnostic center
Authors:
Z. Řehák 1,2; Z. Fojtík 3; J. Vašina 1; R. Koukalová 1; Z. Bortlíček 4; A. Vavrušová 5; P. Němec 6
Authors place of work:
Oddělení nukleární medicíny a PET centrum, Masarykův onkologický ústav, Brno
1; Regionální centrum aplikované molekulární onkologie, Masarykův onkologický ústav, Brno
2; Revmatologická ambulance, Interní hematologická a onkologická klinika, FN Brno a Lékařská fakulta Masarykovy univerzity, Brno
3; Institut biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity, Brno
4; Interní oddělení, Nemocnice Třebíč
5; Revmatologická ambulance, II. interní klinika, FN U sv. Anny, Lékařská fakulta Masarykovy univerzity, Brno
6
Published in the journal:
Čes. Revmatol., 26, 2018, No. 3, p. 122-130.
Category:
Original article
Summary
Polymyalgia rheumatica (PMR) is a chronic, inflammatory disease of unknown cause. Giant cell arteritis (GCA) is a systemic vasculitis affecting medium- and large-sized arteries such as temporal arteries or the aorta and its branches. Diagnosis of these two clinical units could be performed by 18F-FDG PET / CT. The potential of this examination method lies in the ability to detect early inflammatory changes that can be affected by therapy before the development of permanent changes.
A total of 89 patients, 36 (40.4 %) men and 53 (59.6 %) women aged 47-83 years with a median of 69 years, who met the classification criteria for polymyalgia rheumatica, were enrolled. Vascular involvement was detected in 33 (37.1 %) patients in 2-7 (median 4) examined areas of the large arteries. A total of 81 (91.0 %) patients were affected by proximal joint involvement, specifically: shoulder joints in 78 (87.6 %) patients, hip joints in 65 (73.0%) and sternoclavicular joints in 45 (50.6 %) patients. The finding of extraarticular synovial structure involvement was detected in 75 (84.3 %) patients, especially in these localizations: ischial tuberosities or ischiogluteal bursae in 48 (53.9 %) patients, the area between the spinal processes of the lumbar spine in 42 (47.2 %) patients, the area between the spinal processes of the cervical spine in 27 (30.3 %) patients, the subtrochanteric area in 41 (46.1 %) patients, and symphysis in 23 (25.8%) patients.
FDG PET / CT seems to be an advantageous "one-step" examination that can detect the extent of activity in the entire area, can detect PMR or GCA in many forms of these diseases, and is also able to provide evidence of the absence of tumors.
Key words:
FDG, PET, PET/CT, polymyalgia rheumatica, giant cell arteritis
Zdroje
1. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008; 372: 234-45.
2. Salvarani C, Pipitone N, Versari A, Hunder G. Clinical Features of polymyalgia rheumatica and giant cell arteritis. Nat Rev Rheumatol 2012; 8: 509–21.
3. Doran MF, Crowson CS, O´Fallon WM, et al. Trends in the incidence of polymyalgia rheumatica over a 30-year period in Olmsted County, Minnesota, USA. J Rheumatol 2002; 29: 1694–7.
4. Crowson CS, Matteson EL, Myasoedova, E et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 2011; 63: 633–9.
5. Gran JT, Myklebust G. The incidence of polymyalgia rheumatica and temporal arteritis in the county of Aust Agder, south Norway: a prospective study 1987-94. J Rheumatol 1997; 24: 1739–43.
6. Smeeth L, Cook C, Hall AJ. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990-2001. Ann Rheum Dis 2006; 65: 1093–8.
7. Kermani TA, Warrington KJ. Polymyalgia rheumatica. Lancet 2013; 381: 63–72.
8. Salvarani C, Macchioni P, Zizzi F, et al. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. Arthritis Rheum 1991; 34: 351–6.
9. Pamuk ON, Donmez S, Karahan B, et al. Giant cell arteritis and polymyalgia rheumatica in northwestern Turkey. Clinical features and epidemiological data. Clin Exp Rheumatol 2009; 27: 830–3.
10. Dasgupta B, Cimmino MA, Maradit-Kremers H, Schmidt WA, Schirmer M, Salvarani C, et al. 2012 provisional classificatio criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 2012; 71(4): 484–92.
11. Paulley JW, Hughes JP. Giant cell arteritis, or arteritis of the aged. BMJ 1960; 2:1562–67.
12. Wilske KR, Healey LA. Polymyalgia rheumatica: a manifestation of giant cell arteritis. Ann Intern med 1967; 66: 77–91.
13. Blockmans D. Where does polymyalgia rheumatica end and giant cell arteritis begin? Lesson from positron emission tomography studies. Acta Clin Belg 2012; 67: 389–3.
14. Salvarani C, Gabriel SE, O´Fallon WM, Hunder GG. The incidence of giant cell arteritis in Olmsted county, apparent fluctuation in a cyclic pattern. Ann Intern Med 1995; 123: 192–4.
15. Blockmans D, Maes A, Stroobants S, et al. New arguments for a vasculitic nature of polymyalgia rheumatica using positron emission tomography. Rheumatology (Oxford) 1999; 38: 444–7.
16. Healey LA. Long-term follow-up of polymyalgia: evidence for synovitis. Semin Arthritis Rheum 1984; 13: 322–8.
17. Cantini F, Salvarani C, Olivieri I et al. Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case-control study. J Rheumatol 2001; 28: 1049–55.
18. Cantini F, Nicolli L, Nanini C et al. Inflammatory changes of hip synovial structures in polymyalgia rheumatica. Clin Exp Rheumatol 2005; 23: 462–8.
19. Macchioni P, Catanoso MG, Pipitone N, Boiardi L, Salvarani C.Longitudinal examination with shoulder ultrasonography of patients with polymyalgia rheumatica. Rheumatology 2009; 48:1566–9.
20. Patil P, Adizie T, Jain S, Dasgupta B. Imaging indications in polymyalgia rheumatica. Int J Clin Rheumatol 2013; 8(1): 39–48.
21. Blockmans D, De Ceuninck L, Vanderscheueren S, Knockaert D, Mortelmans L, Bobbaers H. Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. Rheumatology 2007; 46: 672–7.
22. Yamashita H, Kubota K, Takahashi Y, Minaminoto R, Morooka M, Ito K, et al. Whole-body fluorodeoxyglucose positron emission tomography/computed tomography in patients with active polymyalgia rheumatica: evidence for distinctive bursitis and large-vessel vasculitis. Mod Rheumatol 2012; 22: 705–11.
23. Moosig F, Czech N, Mehl C, Henze E, Zeuner RA, Kneba M, et al.Correlation between 18-fluorodeoxyglucose accumulation in large vessels and serological markers of inflammation in polymyalgia rheumatica: a quantitative PET study. Ann Rheum Dis 2004; 63: 870–3.
24. Blockmans D, De Ceuninck L, Vanderschueren S, et al. Repetitive 18F-Fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study in 35 patients. Arthritis Rheum 2006; 55(1): 131–7.
25. Fuchs M, Briel M, Daikeler T, Walker UA, Rasch H, Berg S, et al. The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. Eur J Nucl Med Mol Imaging 2012; 39: 344–53.
26. Glaudemans AWJM, de Vries EFJ, Galli F, Dierckx RAJO, Slart RHJA, Signore A. The Use of 18F-FDG-PET/CT for diagnosis and treatment monitoring of inflammatory and infectious diseases. Clin Dev Immunol 2013; 2013: Article ID 623036.
27. Dejaco CH, Ramiro S, Duftner CH, Besson FL, Bley TA, Blockmans D et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis 2018; 0: 1–8.
28. Řehák Z, Szturz P, Křen L, Fojtík Z, Staníček J. Upsampling from aorta and aortic branches. PET/CT hybrid imaging identified 18F-FDG hypermetabolism in inflamed temporal and occipital arteries. Clin Nucl Med 2014; 39(1): e84–6.
29. Muratore F, Pazzola G, Pipitone N, Boiardi L, Salvarani C. Large-vessel involvement in giant cell arteritis and polymyalgia rheumatica. Clin Exp Rheumatol 2014; 32: 106-11.
30. Salvarani C, Barozz L, Cantini F et al. Cervical interspinous bursitis in active polymyalgia rheumatica. Ann Rheum Dis 2008; 67: 758–61.
31. Toriihara A, Seto Y, Yoshida K, Umehara I, Nakagawa T, Liu R, Iwamoto I. F-18 FDG PET/CT of Polymyalgia Rheumatica. Clin Nucl Med 2009; 34: 305–6.
32. Kotani T, Komori T, Kanzaki Y, Takeuchi T, Wakura D, Iimori A, Hirano-Kuwata S, Makino S, Hanafusa T, Ukimora A. FDG-PET/CT of polymyalgia rheumatica. Mod Rheumatol 2011; 21: 334-6.
33. Adams H, Raijmakers P, Smulders Y. Polymyalgia Rheumatica and Interspinous FDG Uptake on PET/CT. Clin Nucl Med 2012;37:502-5.
34. Řehák Z, Szturz P. Comment on: FDG PET in the early diagnosis of large-vessel vasculitis. Eur J Nucl Med Mol Imaging 2014; 41(3): 579–80.
35. Williams M, Jain S, Patil P, Dasgupta B. Contribution of Imaging in Polymyalgia Rheumatica. Joint Bone Spine 2013; 80(2): 228-9.
36. Salvarani C, Barozzi L, Pipitone N, Bajocchi GL, Macchioni PL, Catanoso M, et al. Lumbar interspinous bursitis in active polymyalgia rheumatica. Clinical and Experimental Rheumatology 2013; 31(4): 526–31.
37. Lensen KDF, van Sijl AM, Voskuyl AE, van der Laken CJ, Heymans MW, Comans EFI, et al. Variability in quantitative analysis of atherosclerotic plaque inflammation using 18F-FDG PET/CT. PLoS One. 2017; 12(8): e0181847.
38. Rehak Z, Sprlakova-Pukova A, Bortlicek Z, Fojtik Z, Kazda T,Joukal M, et al. PET/CT imaging in polymyalgia rheumatica: praepubic 18F-FDG uptake correlates with pectineus and adductor longus muscles enthesitis and with tenosynovitis. Radiol Oncol 2017; 51(1): 8–14.
Štítky
Dermatology & STDs Paediatric rheumatology RheumatologyČlánok vyšiel v časopise
Czech Rheumatology
2018 Číslo 3
Najčítanejšie v tomto čísle
- Inhibitors of Janus kinases in the treatment of rheumatoid arthritis.
- Diagnosis of polymyalgia rheumatica and giant cell arteritis using FDG PET and PET / CT imaging – Twelve-year experience of one diagnostic center
- Attenuation of chronic inflammation by exercise or by modifying the intestinal mikrobiome as causal measures on osteoporosis